Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 20 June 1997:
Vol. 276. no. 5320, pp. 1868 - 1872
DOI: 10.1126/science.276.5320.1868
Prev | Table of Contents | Next

Reports

Large Porous Particles for Pulmonary Drug Delivery

David A. Edwards, * Justin Hanes, Giovanni Caponetti, Jeffrey Hrkach, Abdelaziz Ben-Jebria, Mary Lou Eskew, Jeffrey Mintzes, Daniel Deaver, Noah Lotan, Robert Langer *

A new type of inhalation aerosol, characterized by particles of small mass density and large size, permitted the highly efficient delivery of inhaled therapeutics into the systemic circulation. Particles with mass densities less than 0.4 gram per cubic centimeter and mean diameters exceeding 5 micrometers were inspired deep into the lungs and escaped the lungs' natural clearance mechanisms until the inhaled particles delivered their therapeutic payload. Inhalation of large porous insulin particles resulted in elevated systemic levels of insulin and suppressed systemic glucose levels for 96 hours, whereas small nonporous insulin particles had this effect for only 4 hours. High systemic bioavailability of testosterone was also achieved by inhalation delivery of porous particles with a mean diameter (20 micrometers) approximately 10 times that of conventional inhaled therapeutic particles.

D. A. Edwards, A. Ben-Jebria, J. Mintzes, Department of Chemical Engineering, Pennsylvania State University, 204 Fenske Laboratory, University Park, PA 16802, USA.
J. Hanes, J. Hrkach, R. Langer, Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
G. Caponetti, Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA, and Department of Pharmacy, Universite di Parma, 43100 Parma, Italy.
M. L. Eskew, Environmental Resources Research Institute, Pennsylvania State University, Fenske Laboratory, University Park, PA 16802, USA.
D. Deaver, Department of Animal Science, Pennsylvania State University, 324 Henning Building, University Park, PA 16802, USA.
N. Lotan, Department of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel.
*   To whom correspondence should be addressed. E-mail: dxe11{at}psuv.edu (D.A.E.), rlanger{at}mit.edu (R.L.).

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Inhaled Growth Hormone (GH) Compared with Subcutaneous GH in Children with GH Deficiency: Pharmacokinetics, Pharmacodynamics, and Safety.
E. C. Walvoord, A. de la Pena, S. Park, B. Silverman, L. Cuttler, S. R. Rose, G. Cutler, S. Drop, and J. J. Chipman (2009)
J. Clin. Endocrinol. Metab. 94, 2052-2059
   Abstract »    Full Text »    PDF »
Dry Powder Nitroimidazopyran Antibiotic PA-824 Aerosol for Inhalation.
J. C. Sung, L. Garcia-Contreras, J. L. VerBerkmoes, C. A. Peloquin, K. J. Elbert, A. J. Hickey, and D. A. Edwards (2009)
Antimicrob. Agents Chemother. 53, 1338-1343
   Abstract »    Full Text »    PDF »
AIR Inhaled Insulin Versus Subcutaneous Insulin: Pharmacokinetics, glucodynamics, and pulmonary function in asthma.
M. Wolzt, A. de la Pena, P.-Y. Berclaz, F. S. Tibaldi, J. R. Gates, and D. B. Muchmore (2008)
Diabetes Care 31, 735-740
   Abstract »    Full Text »    PDF »
Immunization by a bacterial aerosol.
L. Garcia-Contreras, Y.-L. Wong, P. Muttil, D. Padilla, J. Sadoff, J. DeRousse, W. A. Germishuizen, S. Goonesekera, K. Elbert, B. R. Bloom, et al. (2008)
PNAS 105, 4656-4660
   Abstract »    Full Text »    PDF »
Inhaled Large Porous Particles of Capreomycin for Treatment of Tuberculosis in a Guinea Pig Model.
L. Garcia-Contreras, J. Fiegel, M. J. Telko, K. Elbert, A. Hawi, M. Thomas, J. VerBerkmoes, W. A. Germishuizen, P. B. Fourie, A. J. Hickey, et al. (2007)
Antimicrob. Agents Chemother. 51, 2830-2836
   Abstract »    Full Text »    PDF »
AIR Inhaled Insulin in Subjects With Chronic Obstructive Pulmonary Disease: Pharmacokinetics, glucodynamics, safety, and tolerability.
K. Rave, A. de la Pena, F. S. Tibaldi, L. Zhang, B. Silverman, M. Hausmann, L. Heinemann, and D. B. Muchmore (2007)
Diabetes Care 30, 1777-1782
   Abstract »    Full Text »    PDF »
Pulmonary Anti-inflammatory Effects of Chitosan Microparticles Containing Betamethasone.
Y. C. Huang, A. Vieira, M. K. Yeh, and C. H. Chiang (2007)
Journal of Bioactive and Compatible Polymers 22, 30-41
   Abstract »    PDF »
Dose Response of Inhaled Dry-Powder Insulin and Dose Equivalence to Subcutaneous Insulin Lispro.
K. M. Rave, L. Nosek, A. de la Pena, M. Seger, C. S. Ernest II, L. Heinemann, R. P. Batycky, and D. B. Muchmore (2005)
Diabetes Care 28, 2400-2405
   Abstract »    Full Text »    PDF »
Inhaled insulin for diabetes mellitus.
T. K. Mandal (2005)
Am. J. Health Syst. Pharm. 62, 1359-1364
   Abstract »    Full Text »    PDF »
New Developments in Corticosteroids.
G. Hochhaus (2004)
Proceedings of the ATS 1, 269-274
   Abstract »    Full Text »    PDF »
A Pulmonary Formulation of L-Dopa Enhances Its Effectiveness in a Rat Model of Parkinson's Disease.
R. T. Bartus, D. Emerich, P. Snodgrass-Belt, K. Fu, H. Salzberg-Brenhouse, D. Lafreniere, L. Novak, E.-S. Lo, T. Cooper, and A. S. Basile (2004)
J. Pharmacol. Exp. Ther. 310, 828-835
   Abstract »    Full Text »    PDF »
Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route.
Y. Qi, G. Zhao, D. Liu, Z. Shriver, M. Sundaram, S. Sengupta, G. Venkataraman, R. Langer, and R. Sasisekharan (2004)
PNAS 101, 9867-9872
   Abstract »    Full Text »    PDF »
Fast Onset Medications through Thermally Generated Aerosols.
J. D. Rabinowitz, M. Wensley, P. Lloyd, D. Myers, W. Shen, A. Lu, C. Hodges, R. Hale, D. Mufson, and A. Zaffaroni (2004)
J. Pharmacol. Exp. Ther. 309, 769-775
   Abstract »    Full Text »    PDF »
Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules.
C. Lombry, D. A. Edwards, V. Preat, and R. Vanbever (2004)
Am J Physiol Lung Cell Mol Physiol 286, L1002-L1008
   Abstract »    Full Text »    PDF »
Trojan particles: Large porous carriers of nanoparticles for drug delivery.
N. Tsapis, D. Bennett, B. Jackson, D. A. Weitz, and D. A. Edwards (2002)
PNAS 99, 12001-12005
   Abstract »    Full Text »    PDF »
Inhalation delivery of proteins from ethanol suspensions.
W. S. Choi, G. G. Krishna Murthy, D. A. Edwards, R. Langer, and A. M. Klibanov (2001)
PNAS
   Abstract »    Full Text »    PDF »
Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles.
M. Dutt and G. K. Khuller (2001)
J. Antimicrob. Chemother. 47, 829-835
   Abstract »    Full Text »    PDF »
Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus.
W. T. Cefalu, J. S. Skyler, I. A. Kourides, W. H. Landschulz, C. C. Balagtas, S.-L. Cheng, R. A. Gelfand, and for the Inhaled Insulin Study Group* (2001)
Ann Intern Med 134, 203-207
   Abstract »    Full Text »    PDF »
Therapeutic Efficacy of Poly(DL-Lactide-Co-Glycolide)-Encapsulated Antitubercular Drugs against Mycobacterium tuberculosis Infection Induced in Mice.
M. Dutt and G. K. Khuller (2001)
Antimicrob. Agents Chemother. 45, 363-366
   Abstract »    Full Text »
Inhaled Insulin: An Overview.
J. R. White Jr. and R. K. Campbell (2001)
Clin. Diabetes 19, 13-16
   Abstract »    Full Text »    PDF »
In Vitro Release Behavior of Dextran-Methacrylate Hydrogels Using Doxorubicin and other Model Compounds.
S.-H. Kim and C.-C. Chu (2000)
J Biomater Appl 15, 23-46
   Abstract »    PDF »
Bacterial inactivation by using near- and supercritical carbon dioxide.
A. K. Dillow, F. Dehghani, J. S. Hrkach, N. R. Foster, and R. Langer (1999)
PNAS 96, 10344-10348
   Abstract »    Full Text »    PDF »
Insulin by Inhalation?.
M. Mecikalski (1999)
Chest 116, 581
   Full Text »    PDF »
Recent advances in pulmonary drug delivery using large, porous inhaled particles.
D. A. Edwards, A. Ben-Jebria, and R. Langer (1998)
J Appl Physiol 85, 379-385
   Abstract »    Full Text »    PDF »
NEW APPROACH TO ADMINISTERING INHALED DRUGS.
(1997)
Journal Watch (General) 1997, 7
   Full Text »
Inhalation delivery of proteins from ethanol suspensions.
W. S. Choi, G. G. K. Murthy, D. A. Edwards, R. Langer, and A. M. Klibanov (2001)
PNAS 98, 11103-11107
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)